Patents Examined by Quang Nguyen
  • Patent number: 10006189
    Abstract: A control system controls a construction machine that includes a work machine including a bucket having a plurality of tilting mechanisms. The control system includes: a tilt angle sensor that is provided in the bucket so as to detect tilt angle data including a rotation angle of the bucket about the tilt shaft, the tilt angle sensor being capable of detecting an inclination angle with respect to a horizontal plane; a data acquisition unit to which the tilt angle data is output from the tilt angle sensor; a data fixing unit that fixes the tilt angle data output to the data acquisition unit based on a fixing command to generate fixed data; and a work machine control unit that controls the work machine based on the fixed data until the fixing command is disabled.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Komatsu Ltd.
    Inventor: Jin Kitajima
  • Patent number: 9999685
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO: 1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to the sequence of SEQ ID NO: 1, wherein the isolated nucleic acid molecule specifically leads to the expression in retinal amacrine bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for the gene.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: June 19, 2018
    Inventors: Botond Roska, Josephine Juettner
  • Patent number: 9987347
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 5, 2018
    Inventors: David B. Weiner, Jian Yan, Niranjan Sardesai
  • Patent number: 9970024
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 15, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Prashant Mali, Luhan Yang
  • Patent number: 9970030
    Abstract: Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and/or to enhance homology-directed repair of a cleaved target nucleic acid.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: May 15, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Rachel E. Haurwitz, Andrew P. May, Christopher H. Nye, Megan van Overbeek
  • Patent number: 9955676
    Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-?C46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-? protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-?. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-?C46A mutants.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 1, 2018
    Assignee: Macau University of Science and Technology
    Inventors: Liang Liu, Ting Li, Kam Wai Wong, Zhihong Jiang, Hua Zhou
  • Patent number: 9937233
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: April 10, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Jason P. Schrum, Stephane Bancel, Noubar B. Afeyan, Kenechi Ejebe
  • Patent number: 9932572
    Abstract: The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 3, 2018
    Assignee: Bellicum Pharmaceuticals, Inc.
    Inventors: David Spencer, Wei-Chun Chang
  • Patent number: 9862971
    Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: January 9, 2018
    Inventors: Christian Buchholz, Sabrina Funke, Klaus Cichutek, Roberto Cattaneo
  • Patent number: 9862945
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: January 9, 2018
    Inventors: Kevin Flanigan, Adeline Vulin-Chaffiol, Nicolas Wein
  • Patent number: 9844583
    Abstract: Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain-associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy-chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: December 19, 2017
    Assignee: Indiana University Research and Technology Corp.
    Inventor: Ching-Pin Chang
  • Patent number: 9821016
    Abstract: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 21, 2017
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Ulrich Manfred Lauer, Michael Bitzer, Martina Zimmermann, Sorin Armeanu-Ebinger, Sascha Bossow, Wolfgang Neubert
  • Patent number: 9790477
    Abstract: The present invention provides a transposon for use in genetic manipulation of vertebrate and invertebrate cells.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: October 17, 2017
    Assignee: The Regents of the University of California
    Inventors: Peter W. Atkinson, Susan R. Wessler, Kun Liu
  • Patent number: 9783811
    Abstract: Eukaryotic protein-coding messenger RNAs and non-coding microRNAs are naturally transcribed by type II RNA polymerases (pol-2) but not prokaryotic RNA polymerases. As a result, current eukaryotic RNA and protein production is performed either using eukaryotic pol-2 promoters in hybridomas or mammalian cells or using prokaryotic promoters in bacterial cells. However, because prokaryotic RNA transcription tends to be error-prone, frequent mutation is a big problem. Also, growing hybridomas or mammalian cells is relatively laborious and costly. To overcome these problems, the present invention provides a novel inducible composition and method for producing eukaryotic RNAs and/or their related peptides/proteins directly using eukaryotic pol-2 promoter-driven gene expression in fast growing bacteria, without the need of changing to prokaryotic promoters or growing hybridomas/mammalian cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: October 10, 2017
    Inventors: Shi-Lung Lin, Donald C. Chang
  • Patent number: 9770491
    Abstract: Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to a subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: September 26, 2017
    Assignees: The Trustees of the University of Pennsylvania, Univeristy of Florida Research Foundation, Incorporated
    Inventors: William A Beltran, Gustavo D Aguirre, Samuel G Jacobson, Artur V Cideciyan, Alfred S Lewin, Sanford L Boye, William W Hauswirth, Wen-Tao Deng
  • Patent number: 9764045
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 19, 2017
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John Mcvey, John Gray, Andrew Davidoff
  • Patent number: 9758797
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: September 12, 2017
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9724430
    Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 8, 2017
    Assignee: Intrexon Corporation
    Inventors: Bethany Lynn Merenick, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
  • Patent number: 9718871
    Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 1, 2017
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby Lin
  • Patent number: 9700023
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 11, 2017
    Assignees: DS Pharma Biomedical Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya